Inventiva Pharma: Funding, Investors & Team (Sep 2026)
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small molecule treatments for patients with serious medical needs in fibrosis, lysosomal storage disorders, and oncology. They have developed a pipeline supported by a discovery engine containing a large collection of unique molecules, a research and development facility that they own entirely, and a team with extensive experience in developing compounds targeting nuclear receptors, transcription factors, and epigenetic modulation. By utilizing these assets and expertise, they are progressing two clinical candidates across three indications, in addition to a number of early-stage programs in their pipeline.
Inventiva Pharma has raised $312M across 5 funding rounds on record, the most recent an undisclosed round of $120M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Inventiva Pharma Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Inventiva Pharma Funding Rounds
Inventiva Pharma raised $52.1M in a Post-IPO Debt announced in May 2022.
1.7 years later, an undisclosed round of $27.3M was announced in Jan 2024.
9 months later, an undisclosed round of $103M was announced in Oct 2024.
9 months later, an undisclosed round of $10.0M was announced in Jul 2025.
11 months later, an undisclosed round of $120M was announced in Jun 2026.
Inventiva Pharma Founders and Leadership Team
Contact details for the Inventiva Pharma team: 2 of 3 have an email address on file.
Start 14-day free trial →Inventiva Pharma Funding Compared to Other Biotechnology Startups
Inventiva Pharma's latest round of $120M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Inventiva Pharma in Biotechnology and Daix
Companies Similar to Inventiva Pharma
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Kahimmune Therapeutics is a cutting-edge biotech startup that is repurposing the cancer immunopeptidome to…
Inventiva Pharma Funding FAQs
What does Inventiva Pharma do?
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small molecule treatments for patients with serious medical needs in fibrosis, lysosomal storage disorders, and oncology. They have developed a pipeline supported by a discovery engine containing a large collection of unique molecules, a research and development facility that they own entirely, and a team with extensive experience in developing compounds targeting nuclear receptors, transcription factors, and epigenetic modulation. By utilizing these assets and expertise, they are progressing two clinical candidates across three indications, in addition to a number of early-stage programs in their pipeline.
How much funding has Inventiva Pharma raised?
Inventiva Pharma has raised $312M across 5 rounds on record. The most recent is an undisclosed round of $120M announced in Jun 2026.
When did Inventiva Pharma last raise funding?
Inventiva Pharma's most recent funding round on record is an undisclosed round of $120M, announced in Jun 2026.
Who founded Inventiva Pharma?
FundedIQ lists Andrew Obenshain (Founder), Frederic Cren (Founder), Pierre Broqua (Founder) at Inventiva Pharma.
Where is Inventiva Pharma headquartered?
Inventiva Pharma is based in Daix, Bourgogne, France.
How many employees does Inventiva Pharma have?
Inventiva Pharma is in the 101-250 employee band.
How does Inventiva Pharma's funding compare to other Biotechnology startups?
Inventiva Pharma's latest round of $120M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Inventiva Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Inventiva Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.